KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Working Capital Changes (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Other Working Capital Changes data on record, last reported at $250.6 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 52.25% year-over-year to $250.6 million; the TTM value through Dec 2025 reached $396.0 million, up 97.7%, while the annual FY2025 figure was $396.0 million, 97.7% up from the prior year.
  • Other Working Capital Changes reached $250.6 million in Q4 2025 per VRTX's latest filing, up from $40.9 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $451.3 million in Q4 2023 and bottomed at -$99.2 million in Q1 2024.
  • Average Other Working Capital Changes over 5 years is $78.0 million, with a median of $34.5 million recorded in 2025.
  • The widest YoY moves for Other Working Capital Changes: up 1889.31% in 2022, down 608.27% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at -$15.9 million in 2021, then surged by 1889.31% to $284.5 million in 2022, then skyrocketed by 58.63% to $451.3 million in 2023, then plummeted by 63.53% to $164.6 million in 2024, then soared by 52.25% to $250.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $250.6 million in Q4 2025, $40.9 million in Q3 2025, and $76.4 million in Q2 2025.